Elixir Medical Corporation

Print Article

PRESS RELEASE

Elixir Medical Announces Schedule of Programs for TCT 2016

Live Case Transmission in the US of the Fully Bioresorbable DESolve® NXT Novolimus Eluting Coronary Scaffold System

Sunnyvale, CAOctober 19, 2016 —Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will showcase the first live case demonstration by transmission in the USA of its breakthrough DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System at the 28th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Sunday, October 30. The Elixir-sponsored symposium is also scheduled for Sunday, October 30th  from 6-8 PM.

Elixir will announce new six-month data for its 120µm thin-strut DESolve Cx Fully Bioresorbable Novolimus Eluting Coronary Scaffold System and the four-year data on the DESolve Novolimus eluting scaffold during the scientific conference.  Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST):

Saturday, October 29:

6:00 – 8:00 PM, Washington Convention Center Hall B, Lower Level

Challenging Case: An 80-year-old patient with multiple metal allergies and a bifurcation lesion treated with DESolve (included kissing balloon).
Practical Solution: Can Bioresorbable Scaffold (BRS) be the treatment for a different BRS Restenosis and Bioresorbable Scaffold Recoil?

Sunday, October 30:

10:30 AM, Washington Convention Center, Main Arena
LIVE CASE from Antwerp Cardiovascular Centre, ZNA, Antwerp, Belgium, by Stefan Verheye, MD, Phd
Fully Bioresorbable DESolve® NXT Novolimus Eluting Coronary Scaffold System

Sunday, October 30:

6 – 8 PM, Marriott Marquis Ballroom, Salon 6, Level M2
Elixir-sponsored Symposium:
DESolve® NXT – The Next Breakthrough in BRS Innovation

Chairs

  • Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
  • Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA
  • Roxana Mehran, MD, Mount Sinai Hospital, New York, NY, USA

Panelist Faculty

  • Niels R. Holm, MD, Aarhus University Hospital, Aarhus N, Denmark
  • Holger Nef, MD, PhD Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany
  • Jack Wei Chieh Tan, MD, National Heart Centre Singapore, Singapore

Agenda

  • Session Objectives
  • DESolve Evolution – DESolve, Cx, NXT, NXT Plus
  • DESolve Nx 4-year follow-up
  • DESolve Cx 6-month follow-up
  • DESolve Real World: Europe experience
  • DESolve Real World: Asia experience
  • BIFSORB
  • Indication-specific BRS Therapies – AMITY, PRAVA
  • Session Key Learning

Space is limited: Please register in advance at http://www.crf.org/tct/agenda/satellite-programs

Monday, October 31:

Device Specifications and Clinical Program Update

10:34 AM, Washington Convention Center, Room 305, Level 3
DESyne BD: Prospective, multi-center evaluation of the DESyne BD Novolimus-Eluting Coronary stent: 4-year clinical results.
Ricardo Costa, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

12:45 PM, Washington Convention Center, Room 103B, Level 1
DESolve: TCT 32: Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and Four-Year Clinical and Imaging Results
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

4:22 PM, Washington Convention Center Room 151, Level 1
DESolve NXT, Cx and AMITY: Unique properties and results from 150 µm To 120 µm.
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

Tuesday, November 1:

10:14 AM, Washington Convention Center Room 103B, Level 1
CASE #9: Value of self-expanding properties using DESolve BRS in a bifurcation
Niels R. Holm, MD, Aarhus University Hospital, Aarhus N, Denmark

2:00 PM, Washington Convention Center Room 207, Level 2
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
DESolve: Impact of Different PLLA Polymers and BRS Construction on Implant Technique: From Absorb to DESolve to Fantom to Manli and More

7:22 PM, Marriot Marquis, Salon 1-4, Level M2
Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
DESolve: Thin Struts With Self-Correcting Property (DESolve)

Elixir Medical will have a booth at TCT:  Booth 1309, Exhibit Hall. The booth will be open Sunday, October 30 and Monday, October 31 from 9 am to 5 pm, and Tuesday, November 1 from 9 am to 2 pm.

About Elixir Medical
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com

***

Contact: Donna Collins
Elixir Medical
Ph: (408) 636-2060